Emergence of Chinese Drug Discovery Research: Impact of Hit and Lead Identification
文献类型：期刊论文
| 作者 | Zhou, Caihong1,2; Zhou, Yan1,2; Wang, Jia1,2 ; Zhu, Yue1,2; Deng, Jiejie1,2; Wang, Ming-Wei1,2,3
|
| 刊名 | JOURNAL OF BIOMOLECULAR SCREENING
 |
| 出版日期 | 2015-03 |
| 卷号 | 20期号:3页码:318-329 |
| 关键词 | review drug discovery hit identification lead generation compound library |
| ISSN号 | 1087-0571 |
| DOI | 10.1177/1087057114561950 |
| 文献子类 | Review |
| 英文摘要 | The identification of hits and the generation of viable leads is an early and yet crucial step in drug discovery. In the West, the main players of drug discovery are pharmaceutical and biotechnology companies, while in China, academic institutions remain central in the field of drug discovery. There has been a tremendous amount of investment from the public as well as private sectors to support infrastructure buildup and expertise consolidation relative to drug discovery and development in the past two decades. A large-scale compound library has been established in China, and a series of high-impact discoveries of lead compounds have been made by integrating information obtained from different technology-based strategies. Natural products are a major source in China's drug discovery efforts. Knowledge has been enhanced via disruptive breakthroughs such as the discovery of Boc5 as a nonpeptidic agonist of glucagon-like peptide 1 receptor (GLP-1R), one of the class B G protein-coupled receptors (GPCRs). Most of the original hit identification and lead generation were carried out by academic institutions, including universities and specialized research institutes. The Chinese pharmaceutical industry is gradually transforming itself from manufacturing low-end generics and active pharmaceutical ingredients to inventing new drugs. |
| WOS关键词 | PROTEIN-COUPLED RECEPTOR ; ANTICANCER PRODRUG SIMMITECAN ; GLUCOSE COTRANSPORTER 2 ; PEPTIDE-1 RECEPTOR ; IN-VIVO ; HEPATITIS-B ; BIOLOGICAL EVALUATION ; ALZHEIMERS-DISEASE ; CEREBRAL-ISCHEMIA ; NATURAL-PRODUCTS |
| 资助项目 | National Health and Family Planning Commission of China[2012ZX09304-011] ; National Health and Family Planning Commission of China[2013ZX09401003-005] ; National Health and Family Planning Commission of China[2013ZX09507001] ; National Health and Family Planning Commission of China[2013ZX09507-002] ; Shanghai Science and Technology Development Fund[13DZ2290300] ; Thousand Talents Program in China[00000000] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Biotechnology & Applied Microbiology ; Chemistry |
| 语种 | 英语 |
| WOS记录号 | WOS:000350310000002 |
| 出版者 | SAGE PUBLICATIONS INC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276623]  |
| 专题 | 国家新药筛选中心 |
| 通讯作者 | Wang, Ming-Wei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 200031, Peoples R China; 2.Natl Ctr Drug Screening, Shanghai 201203, Peoples R China; 3.S China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510641, Guangdong, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Caihong,Zhou, Yan,Wang, Jia,et al. Emergence of Chinese Drug Discovery Research: Impact of Hit and Lead Identification[J]. JOURNAL OF BIOMOLECULAR SCREENING,2015,20(3):318-329. |
| APA | Zhou, Caihong,Zhou, Yan,Wang, Jia,Zhu, Yue,Deng, Jiejie,&Wang, Ming-Wei.(2015).Emergence of Chinese Drug Discovery Research: Impact of Hit and Lead Identification.JOURNAL OF BIOMOLECULAR SCREENING,20(3),318-329. |
| MLA | Zhou, Caihong,et al."Emergence of Chinese Drug Discovery Research: Impact of Hit and Lead Identification".JOURNAL OF BIOMOLECULAR SCREENING 20.3(2015):318-329. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。